121 related articles for article (PubMed ID: 8150636)
1. [Cutaneous drug reaction caused by suramin in 4 patients with metastatic prostate cancer].
Wichterich K; Tebbe B; Handke A; Dieckmann KP; Gollnick H
Hautarzt; 1994 Feb; 45(2):84-7. PubMed ID: 8150636
[TBL] [Abstract][Full Text] [Related]
2. Suramin-induced skin reactions.
O'Donnell BP; Dawson NA; Weiss RB; Myers CE; James WD
Arch Dermatol; 1992 Jan; 128(1):75-9. PubMed ID: 1531404
[TBL] [Abstract][Full Text] [Related]
3. Suramin keratosis: a unique skin eruption in a patient receiving suramin for metastatic prostate cancer.
Kenner JR; Sperling LC; Waselenko J; Dawson N; Sau P; Moul JW
J Urol; 1997 Dec; 158(6):2245-6. PubMed ID: 9366363
[No Abstract] [Full Text] [Related]
4. Erythema multiforme induced by suramin.
Katz SK; Medenica MM; Kobayashi K; Vogelzang NJ; Soltani K
J Am Acad Dermatol; 1995 Feb; 32(2 Pt 1):292-3. PubMed ID: 7829723
[No Abstract] [Full Text] [Related]
5. A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response.
Bowden CJ; Figg WD; Dawson NA; Sartor O; Bitton RJ; Weinberger MS; Headlee D; Reed E; Myers CE; Cooper MR
Cancer Chemother Pharmacol; 1996; 39(1-2):1-8. PubMed ID: 8995493
[TBL] [Abstract][Full Text] [Related]
6. Suramin, an active drug for prostate cancer: interim observations in a phase I trial.
Eisenberger MA; Reyno LM; Jodrell DI; Sinibaldi VJ; Tkaczuk KH; Sridhara R; Zuhowski EG; Lowitt MH; Jacobs SC; Egorin MJ
J Natl Cancer Inst; 1993 Apr; 85(8):611-21. PubMed ID: 8468719
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer.
Kobayashi K; Vokes EE; Vogelzang NJ; Janish L; Soliven B; Ratain MJ
J Clin Oncol; 1995 Sep; 13(9):2196-207. PubMed ID: 7666078
[TBL] [Abstract][Full Text] [Related]
8. Severe thrombocytopenia in patients treated with suramin: evidence for an immune mechanism in one.
Tisdale JF; Figg WD; Reed E; McCall NA; Alkins BR; Horne MK
Am J Hematol; 1996 Feb; 51(2):152-7. PubMed ID: 8579057
[TBL] [Abstract][Full Text] [Related]
9. Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma.
Falcone A; Antonuzzo A; Danesi R; Allegrini G; Monica L; Pfanner E; Masi G; Ricci S; Del Tacca M; Conte P
Cancer; 1999 Aug; 86(3):470-6. PubMed ID: 10430255
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of a pharmacokinetically based fixed dosing scheme for suramin.
Reyno LM; Egorin MJ; Eisenberger MA; Sinibaldi VJ; Zuhowski EG; Sridhara R
J Clin Oncol; 1995 Sep; 13(9):2187-95. PubMed ID: 7666077
[TBL] [Abstract][Full Text] [Related]
11. Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy.
Rosen PJ; Mendoza EF; Landaw EM; Mondino B; Graves MC; McBride JH; Turcillo P; deKernion J; Belldegrun A
J Clin Oncol; 1996 May; 14(5):1626-36. PubMed ID: 8622081
[TBL] [Abstract][Full Text] [Related]
12. Suramin in combination with mitomycin C in hormone-resistant prostate cancer. A phase II clinical study.
Rapoport BL; Falkson G; Raats JI; de Wet M; Lotz BP; Potgieter HC
Ann Oncol; 1993 Aug; 4(7):567-73. PubMed ID: 8363988
[TBL] [Abstract][Full Text] [Related]
13. Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer.
Eisenberger MA; Sinibaldi VJ; Reyno LM; Sridhara R; Jodrell DI; Zuhowski EG; Tkaczuk KH; Lowitt MH; Hemady RK; Jacobs SC
J Clin Oncol; 1995 Sep; 13(9):2174-86. PubMed ID: 7666076
[TBL] [Abstract][Full Text] [Related]
14. Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer.
Kelly WK; Scher HI; Mazumdar M; Pfister D; Curley T; Leibertz C; Cohen L; Vlamis V; Dnistrian A; Schwartz M
J Clin Oncol; 1995 Sep; 13(9):2214-22. PubMed ID: 7666079
[TBL] [Abstract][Full Text] [Related]
15. Anaphylactoid reaction with suramin.
Thibault A; Figg WD; Cooper MR; Prindiville SA; Sartor AO; Headlee DJ; Myers CE
Pharmacotherapy; 1993; 13(6):656-7. PubMed ID: 8302692
[TBL] [Abstract][Full Text] [Related]
16. Fixed higher dose schedule of suramin plus hydrocortisone in patients with hormone refractory prostate carcinoma a multicenter Phase II study.
Calvo E; Cortés J; Rodríguez J; Sureda M; Beltrán C; Rebollo J; Martínez-Monge R; Berián JM; de Irala J; Brugarolas A
Cancer; 2001 Nov; 92(9):2435-43. PubMed ID: 11745301
[TBL] [Abstract][Full Text] [Related]
17. UK studies on suramin therapy in hormone resistant prostate cancer.
Kehinde EO; Terry TR; Mistry N; Horsburgh T; Sandhu DP; Bell PR
Cancer Surv; 1995; 23():217-29. PubMed ID: 7621460
[TBL] [Abstract][Full Text] [Related]
18. Acute renal toxicity associated with suramin in the treatment of prostate cancer.
Figg WD; Cooper MR; Thibault A; Headlee D; Humphrey J; Bergan RC; Reed E; Sartor O
Cancer; 1994 Sep; 74(5):1612-4. PubMed ID: 8062193
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of suramin in patients with metastatic renal cell carcinoma.
Dreicer R; Smith DC; Williams RD; See WA
Invest New Drugs; 1999; 17(2):183-6. PubMed ID: 10638490
[TBL] [Abstract][Full Text] [Related]
20. Suramin in adrenocortical cancer: limited efficacy and serious toxicity.
Arlt W; Reincke M; Siekmann L; Winkelmann W; Allolio B
Clin Endocrinol (Oxf); 1994 Sep; 41(3):299-307. PubMed ID: 7955436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
